How AFib is treated today
Two of the more commonly used treatments for AFib are the destruction of tissue by burning with various energy sources or freezing. Current ablation catheter systems consist primarily of either “point-by-point” or “balloon” devices. The ablation procedure, called pulmonary vein isolation (PVI), creates a lesion (scar tissue) to block abnormal electrical signals from passing from the pulmonary veins (PV) to the atria in the beating heart. This is accomplished by generating continuous, long-lasting, transmural (through the heart wall) lesions around the PVs. A successful PVI reduces or eliminates the burden of AFib for patients.
Endorsed by prominent physicians, the CircumBlator™ AF Catheter Ablation System is an innovative ‘single-shot’ radiofrequency (RF) ablation system. CircumBlator addresses physicians’ unmet needs to effectively treat atrial fibrillation (AFib) and reduce the number of repeat procedures for pulmonary vein isolation (PVI). Unique from other ablation technologies, the CircumBlator offers anchor stabilization at the point of electrode-tissue contact. This will provide durable ablation lesions and a permanent PVI the first time. AblaCor’s patent portfolio provides strong protection for the CircumBlator technology.
Recurrent AFib observed in 30% of patients after procedures with current technologies
Current ablation technologies frequently fail to maintain conduction block after ablation treatment. This is often caused by gaps in the lesions. Irregular electrical signals can travel from the PVs through the gaps into the left atrium, causing electrical reconnection of the PVs and recurrence of AFib.
The CircumBlator™ AF Catheter Ablation System is not approved for human use.
The CircumBlator system is designed to be superior to current devices
CircumBlator™ Features and Benefits
CircumBlator™ AF Ablation Catheter
Current devices do not consistently stabilize the ablation catheter against the heart tissue around the PVs, requiring the physician to manually apply contact during the ablation cycle. Making this even more complicated, the procedure is performed in the beating heart. Thirty percent of patients have recurrence of AFib within the first year after ablation.
Continuous tissue contact for precise lesion formation the first time
CircumBlator is designed to offer a durable (long-term) solution to PVI ablation. The table below shows how the “single-shot” CircumBlator is unique from current “point-by-point” and "balloon" ablation devices.
* Unique flow-through anchor and discrete electrode array
* The anchor stabilizes the electrode array for optimum tissue contact around the PV
* Consistent tissue contact yields precise energy delivery for continuous, durable lesion creation in a single procedure
* Ablation and feedback capabilities all in one catheter
* Feedback helps the physician verify lesion quality